Affiliation:
1. Azienda Ospedaliera “SS. Antonio e Biagio e Cesare Arrigo” Alessandria Italy
2. Azienda Ospedaliero‐Universitaria Maggiore della Carità di Novara Novara Italy
3. Department of Translational Medicine University of Eastern Piedmont Novara Italy
4. Aosta Regional Hospital Aosta Italy
5. Città della Salute e della Scienza Torino Italy
6. Departement of Health Science University of Eastern Piedmont Novara Italy
Abstract
SummaryBackgroundTrichophyton (T.) erinacei is a rare but emerging zoonotic dermatophyte that is rarely isolated as a human pathogen, with only a few cases extensively described in the literature.Patients and MethodsWe conducted a systematic search to identify eligible articles reporting demographics, clinical characteristics, and the therapeutic approach regarding T. erinacei infection in humans.Results168 patients affected by T. erinacei were reported in the international literature between inception and November 2023. Only 56 cases (32.1%) were fully described. The median age at diagnosis was 26 years, the female/male ratio was around 2:1. The main source of the disease was the hedgehog. The infection presented with a combination of erythema, scaly plaques, pustules, papules, vesicles, oedema, and erosion; the most common locations were the hands and the head. The most frequently conducted examination was fungal culture, but gene sequencing and mass spectrometry improved both speed and precision in the most recent diagnostic course. Topical clotrimazole and systemic terbinafine were the most chosen treatment.ConclusionsTrichophyton erinacei should be considered in patients with erythematous scaly patches and recent contact with hedgehogs. Terbinafine should be considered as a first‐line effective treatment, griseofulvin and azoles could be considered valid alternatives.